Literature DB >> 23527913

Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.

Vanina Bongard1, Jean Dallongeville, Dominique Arveiler, Jean-Bernard Ruidavets, Philippe Amouyel, Aline Wagner, Jean Ferrières.   

Abstract

BACKGROUND: Controlling low-density lipoprotein (LDL)-cholesterol concentration is of tremendous importance to reduce cardiovascular risk. AIMS: To investigate the attainment of LDL-cholesterol targets recommended in French and European guidelines on cardiovascular prevention, according to levels of cardiovascular risk.
METHODS: Participants aged 35 to 74 years (n=4609) were randomly selected from the general population of three French regions. A standardized data collection was performed to assess cardiovascular risk as described in the French and European guidelines.
RESULTS: Overall, 17.5% of participants were considered to be at high risk and 25.4% at high or very high risk, according to the French and European guidelines, respectively. Only 1.2% of participants with no cardiovascular risk factors according to the French guidelines had an LDL-cholesterol concentration above the recommended target, whereas 82.5% of high-risk subjects did not attain their goal (70.8% among high-risk subjects receiving lipid-lowering therapy). Among untreated people, the median reduction in LDL-cholesterol needed to reach target ranged from 6.6% (lowest-risk groups) to 36.0% (highest-risk subjects). When risk was classified according to the European guidelines, the majority of participants did not reach the recommended LDL-cholesterol targets, irrespective of their level of risk or lipid-lowering therapy.
CONCLUSION: In a majority of primary prevention candidates with multiple risk factors and in most high-risk subjects, LDL-cholesterol targets recommended by French guidelines are not being achieved, either because of insufficient treatment or because subjects are not recognized as being at risk. More stringent targets proposed by the European guidelines are not being achieved in most cases.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23527913     DOI: 10.1016/j.acvd.2012.11.003

Source DB:  PubMed          Journal:  Arch Cardiovasc Dis        ISSN: 1875-2128            Impact factor:   2.340


  6 in total

1.  Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients.

Authors:  Soubra Lama; Domiati Souraya; Fattouh Youssef
Journal:  Int J Clin Pharm       Date:  2017-05-18

Review 2.  Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia.

Authors:  Franck Boccara; Ricardo Dent; Luis Ruilope; Paul Valensi
Journal:  Adv Ther       Date:  2017-07-17       Impact factor: 3.845

3.  One-Year Impact of COVID-19 Lockdown-Related Factors on Cardiovascular Risk and Mental Health: A Population-Based Cohort Study.

Authors:  Emilie Bérard; Samantha Huo Yung Kai; Nicola Coley; Vanina Bongard; Jean Ferrières
Journal:  Int J Environ Res Public Health       Date:  2022-02-01       Impact factor: 3.390

4.  Gender Disparities in Lipid Goal Attainment among Type 2 Diabetes Outpatients with Coronary Heart Disease: Results from the CCMR-3B Study.

Authors:  Xiaomei Zhang; Linong Ji; Xingwu Ran; Benli Su; Qiuhe Ji; Dayi Hu
Journal:  Sci Rep       Date:  2017-10-04       Impact factor: 4.379

5.  Prevalence and management of hypercholesterolemia in France, the Esteban observational study.

Authors:  Jacques Blacher; Amélie Gabet; Alexandre Vallée; Jean Ferrières; Eric Bruckert; Michel Farnier; Valérie Olié
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

6.  Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.

Authors:  Mario Luca Morieri; Valentina Perrone; Chiara Veronesi; Luca Degli Esposti; Margherita Andretta; Mario Plebani; Gian Paolo Fadini; Saula Vigili de Kreutzenberg; Angelo Avogaro
Journal:  Cardiovasc Diabetol       Date:  2021-07-16       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.